Jane Street’s Gain Therapeutics GANX Stock Holding History

Jane Street’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Sell	55,628 -161,255	-74%	-$297K	﹤0.01%	10527
2026 Q1	$421K	Sell	216,883 -25,445	-11%	-$55.4K	﹤0.01%	8449
2025 Q4	$780K	Buy	242,328 +169,878	+234%	+$453K	﹤0.01%	6684
2025 Q3	$128K	Buy	+72,450	New	+$122K	﹤0.01%	9994
2022 Q2	–	Sell	-11,722	Closed	-$48K	–	10059
2022 Q1	$48K	Buy	+11,722	New	+$49K	﹤0.01%	9705
2021 Q2	–	Sell	-22,754	Closed	-$339K	–	9973
2021 Q1	$339K	Buy	+22,754	New	+$299K	﹤0.01%	7497

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's GANX Position: Q2 2026 in Review

Jane Street reduced its Gain Therapeutics (GANX) stake by 74% in Q2 2026, selling an estimated $297K and leaving 55,628 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #10527.

Jane Street first reported a position in GANX in Q1 2021 and has held it in 6 quarters since. The position peaked at $780K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Jane Street held 55,628 shares of Gain Therapeutics worth $113K as of Q2 2026.
Jane Street sold 161,255 Gain Therapeutics shares in Q2 2026, an estimated $297K.
Gain Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10527 holding.
Jane Street first reported a position in Gain Therapeutics in Q1 2021 and has held it in 6 quarters since.
Jane Street's Gain Therapeutics position peaked at $780K in Q4 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.